Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,862,213
  • Shares Outstanding, K 142,825
  • Annual Sales, $ 0 K
  • Annual Income, $ -317,420 K
  • EBIT $ -449 M
  • EBITDA $ -451 M
  • 60-Month Beta 1.30
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.18

Options Overview Details

View History
  • Implied Volatility 81.67% (-18.39%)
  • Historical Volatility 79.78%
  • IV Percentile 10%
  • IV Rank 13.74%
  • IV High 253.75% on 10/21/25
  • IV Low 54.27% on 01/21/25
  • Expected Move (DTE 20) 2.56 (12.77%)
  • Put/Call Vol Ratio 17.63
  • Today's Volume 149
  • Volume Avg (30-Day) 587
  • Put/Call OI Ratio 0.90
  • Today's Open Interest 8,363
  • Open Int (30-Day) 11,203
  • Expected Range 17.48 to 22.60

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.74
  • Number of Estimates 8
  • High Estimate -0.59
  • Low Estimate -0.84
  • Prior Year -0.88
  • Growth Rate Est. (year over year) +15.91%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.21 +10.05%
on 12/09/25
23.96 -16.36%
on 12/08/25
-1.13 (-5.34%)
since 11/26/25
3-Month
11.92 +68.12%
on 09/29/25
25.00 -19.84%
on 10/28/25
+6.89 (+52.40%)
since 09/26/25
52-Week
6.36 +215.09%
on 04/09/25
26.22 -23.57%
on 01/02/25
-4.43 (-18.10%)
since 12/26/24

Most Recent Stories

More News
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors

WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock

WALTHAM, Mass., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p

DYN : 20.04 (-1.52%)
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00...

WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights

- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission...

DYN : 20.04 (-1.52%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...

DYN : 20.04 (-1.52%)
Dyne Therapeutics (DYN) Receives a Buy from Morgan Stanley

In a report released yesterday, Michael Ulz from Morgan Stanley reiterated a Buy rating on Dyne Therapeutics, with a price target of $48.00. The company’s shares closed yesterday at $12.65.Elevate Your...

DYN : 20.04 (-1.52%)
Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)

- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful...

DYN : 20.04 (-1.52%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Dyne Therapeutics Inc. is a muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The company's proprietary platform includes FORCE(TM). Dyne Therapeutics Inc. is based in WALTHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 21.04
2nd Resistance Point 20.69
1st Resistance Point 20.37
Last Price 20.04
1st Support Level 19.70
2nd Support Level 19.35
3rd Support Level 19.03

See More

52-Week High 26.22
Last Price 20.04
Fibonacci 61.8% 18.63
Fibonacci 50% 16.29
Fibonacci 38.2% 13.95
52-Week Low 6.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar